This is a key agreement that strengthens our long-term vision in the fields of regenerative medicine, longevity, and anti-senescence, integrating cutting-edge scientific innovation, advanced nanotechnology platforms, and artificial intelligence–based solutions.
January 7th 2026 — Valencia, Spain and Rochester, New York State, USA
The Crowley Center for Regenerative Biotherapeutics (“the Crowley Center”) and SESDERMA S.L. (“SESDERMA”) are pleased to announce the signing of a comprehensive, global, and exclusive 10year renewable Strategic Alliance.
This multilayered partnership reflects the strong strategic alignment and shared vision of both Senior Management Teams to usher in a new era in the rapidly expanding fields of regenerative medicine, longevity, and antisenescence. It also demonstrates a joint commitment to advancing cutting-edge, science-backed innovations capable of surpassing the current state of the art in regenerative biotherapeutics. Both organizations share core values and similar family-owned corporate structures rooted in a relentless pursuit of excellence and technological disruption, with the goal of establishing a new gold standard in safety, efficacy, bioavailability, and patient experience.
The Alliance is underpinned by a compelling strategic, scientific, technological, and operational rationale that unlocks significant synergies. These include leveraging complementary geographic strengths—facilitating SESDERMA’s expansion into the key U.S. market by capitalizing on the Crowley Center’s sales and marketing capabilities, while accelerating the Crowley Center’s internationalization through SESDERMA’s global network of wholly owned subsidiaries and distributors.
Product development and Nanotech tecnology
On the product development front, the Strategic Alliance places a strong and central emphasis on advanced nanotechnology platforms as a core differentiating pillar. All products developed within the framework of this collaboration will leverage proprietary nanotechnological systems designed to maximize bioavailability, ensure deep tissue penetration, and deliver consistently high levels of efficacy with an outstanding safety profile.
A key focus of the Alliance is the nanoencapsulation and nano-delivery of regenerative actives, including MSC-derived umbilical cord native exosomes, enabling their precise and targeted delivery to the skin and underlying tissues. These nanotechnological carriers significantly enhance stability, biological activity, and clinical performance, achieving highly reliable and reproducible outcomes.
Specific collaboration opportunities include:
- Encapsulation of MSC-derived umbilical cord native exosomes into advanced nano-liposomal systems to enhance deep dermal penetration.
- Co-formulation of exosomes with SESDERMA’s natural regenerative actives, such as highly potent Cacay nut oil and lyophilized botanical extracts.
- Joint development of new regenerative products, cross-licensing of proprietary technologies, and contract manufacturing to strengthen supply-chain efficiency.
Central to the regenerative strategy is the scientifically validated interaction between stem cells and nanotechnology-engineered exosomes. This interaction represents a critical regenerative mechanism, enhancing cellular communication, tissue repair, and biological rejuvenation, and constitutes one of the foundational pillars of the Alliance’s long-term innovation roadmap. .
Artificial Intelligence & Global Longevity Centers
The Alliance will also integrate proprietary artificial intelligence platforms for the early diagnosis of skin cancer, as well as AI-driven solutions applied to longevity medicine and regenerative therapies. These technologies will support advanced diagnostic capabilities, treatment personalization, and continuous optimization of clinical outcomes, reinforcing a precision-medicine approach.
The Strategic Alliance will further expand into advanced longevity technologies, including Transcranial Photobiomodulation Therapy, a non-invasive therapeutic approach based on controlled light stimulation designed to modulate cellular activity, enhance mitochondrial function, and support neuroregeneration and brain health.
Transcranial Photobiomodulation Therapy has demonstrated benefits in improving cerebral blood flow, reducing neuroinflammation, enhancing neuronal metabolism, and promoting neuroplasticity. Through these mechanisms, it supports cognitive performance, mental clarity, stress resilience, and overall neurological well-being, playing a relevant role in healthy aging and longevity medicine.
This technology is increasingly applied as a complementary approach in the management and support of aging-related and neurodegenerative conditions, including cognitive decline, mild cognitive impairment, Alzheimer’s disease, Parkinson’s disease, as well as in chronic fatigue, mood disorders, sleep disturbances, post-stroke recovery, traumatic brain injury, and chronic pain syndromes. It is also utilized to support performance optimization, preventive neurology, and brain health preservation.
Within the framework of the Alliance, Transcranial Photobiomodulation Therapy will be integrated with nanotechnology-based regenerative solutions, stem cell–exosome interactions, and artificial intelligence platforms, enabling the development of comprehensive, personalized, and science-driven longevity and regenerative medicine protocols.
long-term strategic vision
As part of its long-term strategic vision, the Alliance plans to establish a global network of Regenerative Longevity Centers, conceived as centers of excellence dedicated to longevity medicine, regenerative therapies, advanced diagnostics, preventive health, and performance optimization.
Initial target locations include major international cities such as Dubai, Madrid, Valencia, the Dominican Republic, Bogotá, as well as strategic hubs in Asia, including Hong Kong, with further global expansion planned in subsequent phases.
This cooperation is also expected to reinforce regulatory compliance and elevate the integrity of the solutions offered, contributing to the emergence of a new category of regenerative biotherapeutics.
This foundational agreement establishes a platform focused on regenerative aesthetics and reverse aging applications across skincare, beauty, haircare, dental, and vulvovaginal health. It is intended to serve as a springboard for additional components already identified by both Management Teams in their strategic roadmap for future developments in regenerative medicine, including aging-related pathologies such as neurodegenerative diseases, orthopedics, rheumatology, severe pain management, and oncology. Further announcements will follow as new initiatives are integrated into the Alliance.
About The Crowley Center for Regenerative Biotherapeutics
Founded in 1987 by Professor Michael Crowley, JD, The Crowley Center for Regenerative Biotherapeutics is a family-owned scientific company advancing all-natural biologic innovations in regenerative medicine, aesthetics, and longevity. Restructured under its current corporate name in 2017, the Center develops proprietary platforms designed to restore the body, extend vitality, and redefine what’s possible in patient care.
At the foundation of its science is Regenerelle®, the Center’s flagship regenerative biologics platform producing the world’s largest yield of low passage, medical grade mesenchymal stem cell innovations and isolating EXACT™ Certified Pure Age Zero™ exosomes for advanced recovery, rejuvenation, and longevity applications.
Regenerelle® also manufactures the Center’s newest performance longevity innovations, including:
- Nöotrosomes™ is a cognitive longevity and brain performance product for professional athletes in high-impact sports. Manufactured by Regenerelle, it is offered through a dedicated athlete program developed with legendary NFL quarterback Bernie Kosar via Renewing Athletes Lives LLC, supporting sustained mental sharpness, cognitive durability, and long-term brain health.
- Resilièlle Cosmetics LLC, a luxury regenerative skincare division bringing biologic longevity science into advanced aesthetic beauty
The Center’s oncology and wound-healing division includes Sanatela® Matrix, a lab-developed ECM platform technology designed to help predict therapies capable of eradicating cancer stem cells. Sanatela® Matrix is also engineered for both human and veterinary use as an absorbable wound and burn dressing.
In 2017, quality engineering expert Erin Crowley joined the leadership team to drive scalable quality manufacturing and commercialization. Together, the Crowley Center continues building a clear pathway to the future—where regenerative biology powers longer life, stronger recovery, and elevated human performance.
About SESDERMA S.L.
SESDERMA Group is a leading Spanish dermatological laboratory with a presence in more than 90 markets worldwide and over 35 years of experience in dermatological innovation. Founded in 1989 by Dr. Gabriel Serrano, a pioneering dermatologist and one of the early leaders in the application of nanotechnology to dermatology, the Group focuses its efforts on the research, development, formulation, and manufacturing of advanced dermocosmetic products, nano-nutraceuticals, and medical-aesthetic solutions.
Today, SESDERMA represents dermatological innovation at the service of skin health, longevity, and overall well-being. The Group’s portfolio includes the brands Sesderma, Mediderma, SophieSkin, and Dr. Serrano
Dr. Gabriel Serrano, Chairman of the SESDERMA Group, said “This Strategic Alliance represents a major milestone in our long-term vision to advance dermatology, regenerative medicine, and longevity through science-driven innovation. By combining SESDERMA’s decades of leadership in nanotechnology and advanced dermocosmetic delivery systems with the Crowley Center’s pioneering regenerative biologics, exosome science, and longevity platforms, we are creating a unique and powerful ecosystem for the future of medicine. This collaboration allows us to move beyond traditional aesthetics toward truly regenerative and preventive solutions—integrating nanotechnology, artificial intelligence, photobiomodulation, and stem cell–exosome interactions—to improve health, vitality, and quality of life on a global scale.” [Dr. Gabriel Serrano, MD], Founder and Chairman of the SESDERMA Group.
Dr. Michael Crowley, Chairman of the Crowley Center for Regenerative Biotherapeutics, said “Sesderma’s liposomal delivery technology is truly world-class—decades ahead of the curve—and its synergy with our Regenerelle Age Zero™ nano technologies is extraordinary. As two family-owned companies aligned in innovation, commercialization, and humanitarian purpose, we’re launching a platform designed to bring advanced longevity science and regenerative medicine to more people than ever before. Our mission is simple: to help the body and mind receive the precise signals and bioavailable ingredients they need to support repair, resilience, and healthier aging—so people can live longer with greater vitality and quality of life.” — [Prof. Michael Crowley JD], CEO and Co-Managing Member, The Crowley Center for Regenerative Biotherapeutics LLC.
WINDOME BANKING PARTNERS SAS advised both parties on the design, structuring, and evaluation of the Strategic Alliance.
Addresses:
The Crowley Center for Regenerative Biotherapeutics LLC
2290 East Ave
Rochester, NY 14610
Estados Unidos.
www.atventurecenter.com
Grupo SESDERMA
C/ Grabador Esteve 8
46004 Valencia
España
Dirección web: www.sesderma.com
